You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEdoxaban
Accession NumberDB09075
TypeSmall Molecule
GroupsApproved
DescriptionEdoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • DU 176
  • DU 176b
  • DU-176
  • DU-176b
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated15 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated15 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet15 mgOralDaiichi Sankyo IncNot applicableNot applicableCanada
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet30 mgOralDaiichi Sankyo IncNot applicableNot applicableCanada
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet60 mgOralDaiichi Sankyo IncNot applicableNot applicableCanada
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe Gmb H2015-06-19Not applicableEu
SavaysaTablet, film coated60 mg/1OralDaiichi Sankyo, Inc.2015-01-12Not applicableUs
SavaysaTablet, film coated15 mg/1OralDaiichi Sankyo, Inc.2015-01-12Not applicableUs
SavaysaTablet, film coated30 mg/1OralDaiichi Sankyo, Inc.2015-01-12Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LixianaDaiichi-Sankyo
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Edoxaban tosylate
480449-71-6
ThumbNot applicableDBSALT001717
Edoxaban tosylate monohydrate
1229194-11-9
ThumbNot applicableDBSALT001718
Categories
UNIINDU3J18APO
CAS number480449-70-5
WeightAverage: 548.06
Monoisotopic: 547.1768513
Chemical FormulaC24H30ClN7O4S
InChI KeyHGVDHZBSSITLCT-JLJPHGGASA-N
InChI
InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1
IUPAC Name
N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-2-amido}cyclohexyl]ethanediamide
SMILES
CN(C)C(=O)[[email protected]]1CC[[email protected]](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1
Pharmacology
IndicationEdoxaban is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
Structured Indications
PharmacodynamicsAdministration of edoxaban results in prolongation of clotting time tests such as aPTT (activated partial thromboplastin time), PT (prothrombin time), and INR (international normalized ratio).
Mechanism of actionEdoxaban is a selective inhibitor of factor Xa, a serine endopeptidase of the clotting cascade required for cleavage of prothrombin into thrombin.
TargetKindPharmacological actionActionsOrganismUniProt ID
Coagulation factor XProteinyes
inhibitor
HumanP00742 details
Related Articles
AbsorptionFollowing oral administration, peak plasma edoxaban concentrations are observed within 1-2 hours. Absolute bioavailability is 62%.
Volume of distribution

The steady state volume of distribution is 107 L.

Protein bindingIn vitro plasma protein binding is ~55%.
Metabolism

Edoxaban is not extensively metabolized by CYP3A4 resulting in minimal drug-drug interactions. However, it does interact with drugs that inhibit p-gp (p-glycoprotein), which is used to transport edoxaban across the intestinal wall. Unchanged edoxaban is the predominant form in plasma. There is minimal metabolism via hydrolysis (mediated by carboxylesterase 1), conjugation, and oxidation by CYP3A4. The predominant metabolite M-4, formed by hydrolysis, is human-specific and active and reaches less than 10% of the exposure of the parent compound in healthy subjects. Exposure to the other metabolites is less than 5% of exposure to edoxaban.

Route of eliminationEdoxaban is eliminated primarily as unchanged drug in urine. Renal clearance (11 L/hour) accounts for approximately 50% of the total clearance of edoxaban (22 L/hour). Metabolism and biliary/intestinal excretion account for the remaining clearance.
Half lifeThe terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours.
Clearance

22 L/hr

ToxicityPremature discontinuation of any oral anticoagulant, including edoxaban, in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If edoxaban is discontinued for reasons other than pathological bleeding or completion of a course of therapy, consider the use of another anticoagulant. Edoxaban increases the risk of potentially fatal major bleeding such as intracranial hemorrhage and gastrointestinal bleeding. Patients should be educated on how to watch for signs of major and minor bleeding and when to seek medical help. Co-administration of other anti-coagulants, anti-platelets, or thrombolytics may increase the risk of bleeding and should therefore be avoided.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Edoxaban.Approved, Investigational
AbciximabEdoxaban may increase the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Edoxaban.Approved
AcenocoumarolEdoxaban may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Edoxaban can be increased when it is combined with Acetaminophen.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Edoxaban.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Edoxaban.Approved
AfatinibThe serum concentration of Edoxaban can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Edoxaban can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Edoxaban can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Edoxaban can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Edoxaban can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Edoxaban.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Allylestrenol.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Edoxaban.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Edoxaban.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Edoxaban.Approved
AltrenogestThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Edoxaban.Investigational
AmantadineThe serum concentration of Edoxaban can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Edoxaban.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Edoxaban.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Edoxaban can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Edoxaban.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Edoxaban.Approved
AmiodaroneThe serum concentration of Edoxaban can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Edoxaban can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Edoxaban can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Edoxaban can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Edoxaban can be increased when it is combined with Amsacrine.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Edoxaban.Approved
AncrodEdoxaban may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Edoxaban.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Edoxaban.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Edoxaban.Approved
Antithrombin III humanEdoxaban may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Edoxaban.Approved
ApremilastApremilast may increase the anticoagulant activities of Edoxaban.Approved, Investigational
ArdeparinEdoxaban may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanEdoxaban may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Edoxaban.Investigational
AstemizoleThe serum concentration of Edoxaban can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Edoxaban can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Edoxaban can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Edoxaban can be increased when it is combined with Atorvastatin.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Edoxaban.Withdrawn
AzelastineThe serum concentration of Edoxaban can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Edoxaban can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Edoxaban.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Edoxaban.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Edoxaban.Approved, Investigational
BecaplerminEdoxaban may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Edoxaban.Approved
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Edoxaban.Withdrawn
BenzocaineThe serum concentration of Edoxaban can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Edoxaban can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Edoxaban.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Edoxaban.Investigational
BiperidenThe serum concentration of Edoxaban can be increased when it is combined with Biperiden.Approved
BivalirudinEdoxaban may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Edoxaban can be decreased when it is combined with Boceprevir.Approved
BosutinibThe serum concentration of Edoxaban can be increased when it is combined with Bosutinib.Approved
BromfenacBromfenac may increase the anticoagulant activities of Edoxaban.Approved
BromocriptineThe serum concentration of Edoxaban can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Edoxaban.Investigational
BuprenorphineThe serum concentration of Edoxaban can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Edoxaban can be increased when it is combined with Buspirone.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Edoxaban.Investigational
CabazitaxelThe serum concentration of Edoxaban can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Edoxaban.Approved
CaffeineThe serum concentration of Edoxaban can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Edoxaban can be increased when it is combined with Candesartan.Approved
CangrelorCangrelor may increase the anticoagulant activities of Edoxaban.Approved
CaptoprilThe serum concentration of Edoxaban can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Edoxaban can be increased when it is combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Edoxaban can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Edoxaban can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the anticoagulant activities of Edoxaban.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Edoxaban.Approved, Investigational
CertoparinEdoxaban may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe serum concentration of Edoxaban can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Edoxaban.Withdrawn
ChlorpromazineThe serum concentration of Edoxaban can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Edoxaban can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Edoxaban can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Edoxaban can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Edoxaban can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Edoxaban can be increased when it is combined with Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Edoxaban.Approved
CimetidineThe serum concentration of Edoxaban can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Edoxaban can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Edoxaban.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Edoxaban can be increased when it is combined with Citalopram.Approved
Citric AcidEdoxaban may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Edoxaban can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Edoxaban can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Edoxaban can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Edoxaban.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Edoxaban.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Edoxaban can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Edoxaban can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Edoxaban can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Edoxaban can be increased when it is combined with Colforsin.Experimental
CollagenaseThe risk or severity of adverse effects can be increased when Edoxaban is combined with Collagenase.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Edoxaban.Approved
CrizotinibThe serum concentration of Edoxaban can be increased when it is combined with Crizotinib.Approved
CurcuminCurcumin may increase the anticoagulant activities of Edoxaban.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Edoxaban.Approved
CyclophosphamideThe serum concentration of Edoxaban can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Edoxaban can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the anticoagulant activities of Edoxaban.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Edoxaban.Approved
DaclatasvirThe serum concentration of Edoxaban can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Edoxaban can be increased when it is combined with Dactinomycin.Approved
DalteparinEdoxaban may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEdoxaban may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibThe serum concentration of Edoxaban can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Edoxaban can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Edoxaban.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Edoxaban.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Edoxaban is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Edoxaban.Investigational
DesipramineThe serum concentration of Edoxaban can be increased when it is combined with Desipramine.Approved
DesirudinEdoxaban may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Edoxaban can be increased when it is combined with Desloratadine.Approved, Investigational
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Edoxaban.Investigational
DesogestrelThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe serum concentration of Edoxaban can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranEdoxaban may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Edoxaban may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Edoxaban may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Edoxaban may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Edoxaban can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Edoxaban can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolEdoxaban may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Edoxaban.Approved
DienogestThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Edoxaban.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Edoxaban.Approved
DigoxinThe serum concentration of Edoxaban can be increased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Edoxaban can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Edoxaban can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Edoxaban can be increased when it is combined with Dipyridamole.Approved
DitazoleDitazole may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Edoxaban.Approved
DoxazosinThe serum concentration of Edoxaban can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Edoxaban can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Edoxaban can be increased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Edoxaban can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Edoxaban can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Edoxaban.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Edoxaban.Investigational
DydrogesteroneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Edoxaban.Approved
E6201E6201 may increase the anticoagulant activities of Edoxaban.Investigational
EbselenEbselen may increase the anticoagulant activities of Edoxaban.Investigational
Edetic AcidEdoxaban may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
ElbasvirThe serum concentration of Edoxaban can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Edoxaban can be increased when it is combined with Enalapril.Approved, Vet Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Edoxaban.Approved, Investigational
EnoxaparinEdoxaban may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Edoxaban can be increased when it is combined with Enzalutamide.Approved
EpinastineEpinastine may increase the anticoagulant activities of Edoxaban.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Edoxaban.Approved
eplivanserineeplivanserine may increase the anticoagulant activities of Edoxaban.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Edoxaban.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Edoxaban.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Edoxaban.Approved
ErgonovineThe serum concentration of Edoxaban can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Edoxaban can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Edoxaban can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Edoxaban.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Edoxaban.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Edoxaban can be increased when it is combined with Estramustine.Approved
EstriolEstriol may decrease the anticoagulant activities of Edoxaban.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Edoxaban.Approved
EstroneEstrone may decrease the anticoagulant activities of Edoxaban.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Edoxaban.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Edoxaban.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Edoxaban.Approved
Ethyl biscoumacetateEdoxaban may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Edoxaban.Approved
EtonogestrelThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoposideThe serum concentration of Edoxaban can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Edoxaban.Approved, Investigational
EtravirineThe serum concentration of Edoxaban can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Edoxaban.Approved
exisulindexisulind may increase the anticoagulant activities of Edoxaban.Investigational
FelodipineThe serum concentration of Edoxaban can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Edoxaban.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Edoxaban.Approved
FentanylThe serum concentration of Edoxaban can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Edoxaban can be increased when it is combined with Fexofenadine.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Edoxaban.Approved
FidaxomicinThe serum concentration of Edoxaban can be increased when it is combined with Fidaxomicin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
FluconazoleThe serum concentration of Edoxaban can be increased when it is combined with Fluconazole.Approved
FluindioneEdoxaban may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Edoxaban.Vet Approved
FluoxetineThe serum concentration of Edoxaban can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Edoxaban can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Edoxaban can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Edoxaban can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Edoxaban.Approved, Investigational
FluvoxamineThe serum concentration of Edoxaban can be increased when it is combined with Fluvoxamine.Approved, Investigational
FondaparinuxEdoxaban may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEdoxaban may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateEdoxaban may increase the anticoagulant activities of Gabexate.Investigational
GarlicThe serum concentration of Edoxaban can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of Edoxaban can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Edoxaban can be increased when it is combined with Genistein.Investigational
GestodeneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Gestrinone.Approved
GlyburideThe serum concentration of Edoxaban can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Edoxaban can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Edoxaban can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Edoxaban can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Edoxaban can be increased when it is combined with Haloperidol.Approved
HeminHemin may increase the anticoagulant activities of Edoxaban.Approved
HeparinEdoxaban may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Edoxaban.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Edoxaban.Investigational
HirulogEdoxaban may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Edoxaban.Investigational
HydrocortisoneThe serum concentration of Edoxaban can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Edoxaban.Approved
IbudilastIbudilast may increase the anticoagulant activities of Edoxaban.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Edoxaban.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Edoxaban.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Edoxaban.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Edoxaban.Approved, Nutraceutical
IdelalisibThe serum concentration of Edoxaban can be increased when it is combined with Idelalisib.Approved
idraparinuxEdoxaban may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
IloprostIloprost may increase the anticoagulant activities of Edoxaban.Approved, Investigational
ImatinibThe serum concentration of Edoxaban can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Edoxaban can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Edoxaban can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Edoxaban.Investigational
IndomethacinThe serum concentration of Edoxaban can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Edoxaban.Withdrawn
IsavuconazoniumThe serum concentration of Edoxaban can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Edoxaban.Withdrawn
ItraconazoleThe serum concentration of Edoxaban can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Edoxaban can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Edoxaban can be increased when it is combined with Ivermectin.Approved, Vet Approved
Kct 0809Kct 0809 may increase the anticoagulant activities of Edoxaban.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Edoxaban.Experimental
KetamineThe serum concentration of Edoxaban can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinKetanserin may increase the anticoagulant activities of Edoxaban.Investigational
KetoconazoleThe serum concentration of Edoxaban can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Edoxaban.Approved
LansoprazoleThe serum concentration of Edoxaban can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Edoxaban can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Edoxaban.Approved, Investigational
LepirudinEdoxaban may increase the anticoagulant activities of Lepirudin.Approved
LevofloxacinThe serum concentration of Edoxaban can be increased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevothyroxineThe serum concentration of Edoxaban can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Edoxaban can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Edoxaban.Approved
LiothyronineThe serum concentration of Edoxaban can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Edoxaban can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Edoxaban can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Edoxaban.Investigational
LomitapideThe serum concentration of Edoxaban can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Edoxaban can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Edoxaban can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Edoxaban can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Edoxaban.Approved
LosartanThe serum concentration of Edoxaban can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Edoxaban.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Edoxaban.Approved
LumacaftorThe serum concentration of Edoxaban can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Edoxaban.Approved, Investigational
LynestrenolThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Edoxaban.Approved
MaprotilineThe serum concentration of Edoxaban can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Edoxaban.Approved
MebendazoleThe serum concentration of Edoxaban can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Edoxaban.Approved
MefloquineThe serum concentration of Edoxaban can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Edoxaban can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
MeprobamateThe serum concentration of Edoxaban can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the anticoagulant activities of Edoxaban.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Edoxaban.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Edoxaban.Withdrawn
MethadoneThe serum concentration of Edoxaban can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Edoxaban.Experimental
MetoprololThe serum concentration of Edoxaban can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Edoxaban can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Edoxaban can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Edoxaban.Approved, Illicit
MifepristoneThe serum concentration of Edoxaban can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Edoxaban.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Edoxaban.Approved
MitomycinThe serum concentration of Edoxaban can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Edoxaban can be increased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may increase the anticoagulant activities of Edoxaban.Investigational
MorphineThe serum concentration of Edoxaban can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Edoxaban.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Edoxaban.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Edoxaban.Approved
NadroparinEdoxaban may increase the anticoagulant activities of Nadroparin.Approved
NafamostatEdoxaban may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineNaftifine may increase the anticoagulant activities of Edoxaban.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Edoxaban.Investigational
NaltrexoneThe serum concentration of Edoxaban can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
NaringeninThe serum concentration of Edoxaban can be increased when it is combined with Naringenin.Experimental
NCX 4016NCX 4016 may increase the anticoagulant activities of Edoxaban.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Edoxaban.Approved, Withdrawn
NelfinavirThe serum concentration of Edoxaban can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Edoxaban can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Edoxaban.Approved
NicardipineThe serum concentration of Edoxaban can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Edoxaban can be increased when it is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Edoxaban.Approved
NilotinibThe serum concentration of Edoxaban can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Edoxaban is combined with Nintedanib.Approved
NisoldipineThe serum concentration of Edoxaban can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Edoxaban can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Edoxaban can be increased when it is combined with Nitrendipine.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Edoxaban.Investigational
NomegestrolThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Norethisterone.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Edoxaban.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Edoxaban is combined with Obinutuzumab.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Edoxaban.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Edoxaban.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Edoxaban is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Edoxaban.Approved
OmeprazoleThe serum concentration of Edoxaban can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Edoxaban.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Edoxaban.Vet Approved
OtamixabanEdoxaban may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Edoxaban.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Edoxaban.Withdrawn
P-NitrophenolThe serum concentration of Edoxaban can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Edoxaban can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Edoxaban can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Edoxaban can be increased when it is combined with Pantoprazole.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Edoxaban.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Edoxaban.Approved
ParoxetineThe serum concentration of Edoxaban can be increased when it is combined with Paroxetine.Approved, Investigational
Pentosan PolysulfateEdoxaban may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Edoxaban.Approved, Investigational
PerindoprilThe serum concentration of Edoxaban can be increased when it is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Edoxaban is combined with Pethidine.Approved
PhenindioneEdoxaban may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Edoxaban can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonEdoxaban may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Edoxaban.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Edoxaban.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Edoxaban.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Edoxaban.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Edoxaban.Investigational
Platelet Activating FactorThe serum concentration of Edoxaban can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Edoxaban.Approved
PonatinibThe serum concentration of Edoxaban can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Edoxaban can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Edoxaban.Approved
PravastatinThe serum concentration of Edoxaban can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Edoxaban can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Edoxaban can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Edoxaban can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Edoxaban can be increased when it is combined with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Edoxaban.Investigational
PromethazineThe serum concentration of Edoxaban can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may increase the anticoagulant activities of Edoxaban.Approved
PropafenoneThe serum concentration of Edoxaban can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Edoxaban can be increased when it is combined with Propranolol.Approved, Investigational
Protein CEdoxaban may increase the anticoagulant activities of Protein C.Approved
Protein S humanEdoxaban may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEdoxaban may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Edoxaban can be increased when it is combined with Protriptyline.Approved
PTC299PTC299 may increase the anticoagulant activities of Edoxaban.Investigational
QuercetinThe serum concentration of Edoxaban can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Edoxaban can be increased when it is combined with Quinacrine.Approved
QuinestrolQuinestrol may decrease the anticoagulant activities of Edoxaban.Approved
QuinidineThe serum concentration of Edoxaban can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Edoxaban can be increased when it is combined with Quinine.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Edoxaban.Investigational
RanitidineThe serum concentration of Edoxaban can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Edoxaban can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Edoxaban can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Edoxaban can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Edoxaban can be increased when it is combined with Reserpine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Edoxaban.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Edoxaban.Approved
ReviparinEdoxaban may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Edoxaban.Approved
RifampicinThe serum concentration of Edoxaban can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Edoxaban can be increased when it is combined with Rilpivirine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Edoxaban.Approved
RitonavirThe serum concentration of Edoxaban can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanEdoxaban may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Edoxaban.Investigational, Withdrawn
RolapitantThe serum concentration of Edoxaban can be increased when it is combined with Rolapitant.Approved
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Edoxaban.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Edoxaban.Approved
S EquolS Equol may decrease the anticoagulant activities of Edoxaban.Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Edoxaban.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Edoxaban.Approved
SaquinavirThe serum concentration of Edoxaban can be increased when it is combined with Saquinavir.Approved, Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Edoxaban.Investigational
ScopolamineThe serum concentration of Edoxaban can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Edoxaban.Investigational
SelegilineThe serum concentration of Edoxaban can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the anticoagulant activities of Edoxaban.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Edoxaban.Approved, Investigational
SertralineThe serum concentration of Edoxaban can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Edoxaban.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Edoxaban.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Edoxaban.Approved
SirolimusThe serum concentration of Edoxaban can be increased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Edoxaban can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Edoxaban can be increased when it is combined with Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Edoxaban.Investigational
St. John's WortThe metabolism of Edoxaban can be increased when combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Edoxaban can be increased when it is combined with Staurosporine.Experimental
StreptokinaseStreptokinase may increase the anticoagulant activities of Edoxaban.Approved
StreptozocinThe serum concentration of Edoxaban can be decreased when it is combined with Streptozocin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Edoxaban.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Edoxaban.Approved
SulfinpyrazoneThe serum concentration of Edoxaban can be increased when it is combined with Sulfinpyrazone.Approved
SulindacSulindac may increase the anticoagulant activities of Edoxaban.Approved
SulodexideEdoxaban may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Edoxaban can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Edoxaban can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Edoxaban.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Edoxaban.Approved
TacrineThe serum concentration of Edoxaban can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Edoxaban can be increased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Edoxaban.Approved, Investigational
TamoxifenThe serum concentration of Edoxaban can be increased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Edoxaban can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Edoxaban can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Edoxaban can be increased when it is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Edoxaban.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Edoxaban.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Edoxaban.Vet Approved
TerazosinThe serum concentration of Edoxaban can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Edoxaban can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may increase the anticoagulant activities of Edoxaban.Approved
TesmilifeneThe serum concentration of Edoxaban can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Edoxaban can be increased when it is combined with Testosterone.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Edoxaban.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Edoxaban.Approved
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Edoxaban.Approved
TiboloneTibolone may increase the anticoagulant activities of Edoxaban.Approved
TicagrelorThe serum concentration of Edoxaban can be increased when it is combined with Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Edoxaban.Approved
TinoridineTinoridine may increase the anticoagulant activities of Edoxaban.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Edoxaban.Approved
TipranavirThe serum concentration of Edoxaban can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Edoxaban.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Edoxaban.Approved
TolmetinTolmetin may increase the anticoagulant activities of Edoxaban.Approved
TolvaptanThe serum concentration of Edoxaban can be increased when it is combined with Tolvaptan.Approved
TositumomabThe risk or severity of adverse effects can be increased when Edoxaban is combined with Tositumomab.Approved
TranilastTranilast may increase the anticoagulant activities of Edoxaban.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Edoxaban.Approved
TrazodoneThe serum concentration of Edoxaban can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the anticoagulant activities of Edoxaban.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Edoxaban.Approved
TrifluoperazineThe serum concentration of Edoxaban can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Edoxaban can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Edoxaban.Approved
TrimethoprimThe serum concentration of Edoxaban can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Edoxaban can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Edoxaban.Approved
TroleandomycinThe serum concentration of Edoxaban can be increased when it is combined with Troleandomycin.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Edoxaban.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Edoxaban.Approved, Investigational
VenlafaxineThe serum concentration of Edoxaban can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Edoxaban can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Edoxaban can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Edoxaban can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Edoxaban can be increased when it is combined with Vinorelbine.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Edoxaban.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Edoxaban.Approved
WarfarinEdoxaban may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEdoxaban may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Edoxaban may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Edoxaban.Approved
ZeranolZeranol may decrease the anticoagulant activities of Edoxaban.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Edoxaban.Approved
ZileutonZileuton may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Edoxaban can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Edoxaban.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Turpie AG: New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008 Jan;29(2):155-65. Epub 2007 Dec 19. [PubMed:18096568 ]
  2. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S: Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010 Jul;50(7):743-53. doi: 10.1177/0091270009351883. Epub 2010 Jan 15. [PubMed:20081065 ]
  3. Yeh CH, Hogg K, Weitz JI: Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015 May;35(5):1056-65. doi: 10.1161/ATVBAHA.115.303397. Epub 2015 Mar 19. [PubMed:25792448 ]
  4. Senoo K, Lip GY: Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. Semin Thromb Hemost. 2015 Mar;41(2):146-53. doi: 10.1055/s-0035-1544156. Epub 2015 Feb 15. [PubMed:25682085 ]
  5. Parasrampuria DA, Truitt KE: Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet. 2015 Nov 30. [PubMed:26620048 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 20:12.04.14
PDB EntriesNot Available
FDA labelDownload (600 KB)
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral15 mg
TabletOral30 mg
TabletOral60 mg
Tablet, film coatedOral15 mg
Tablet, film coatedOral30 mg
Tablet, film coatedOral60 mg
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral60 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US2013026553 No2011-08-222031-08-22Us
US7365205 No2003-06-122023-06-12Us
US9149532 No2008-03-282028-03-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
pKa6.7FDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.0114 mg/mLALOGPS
logP1.61ALOGPS
logP0.9ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)10.74ChemAxon
pKa (Strongest Basic)6.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area136.63 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity140.14 m3·mol-1ChemAxon
Polarizability56.31 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type endopeptidase activity
Specific Function:
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name:
F10
Uniprot ID:
P00742
Molecular Weight:
54731.255 Da
References
  1. Turpie AG: New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008 Jan;29(2):155-65. Epub 2007 Dec 19. [PubMed:18096568 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, Okudaira N, Izumi T: Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos. 2014 Apr;42(4):520-8. doi: 10.1124/dmd.113.054866. Epub 2014 Jan 23. [PubMed:24459178 ]
Comments
comments powered by Disqus
Drug created on May 15, 2015 10:35 / Updated on December 07, 2016 02:40